Publication:
Efficacy and safety of CT-P13 as first- and second-line treatment in patients with ankylosing spondylitis

Thumbnail Image

Organizational Units

Authors

Uslu, Sadettin
Gulle, Semih
Sen, Gercek
Capar, Sedat
Senel, Soner
Dalkilic, Ediz
Akar, Servet
Koca, Sueleyman Serdar
Tufan, Abdurrahman
Yazici, Ayten

Advisor

Language

Publisher:

MDPI

Journal Title

Journal ISSN

Volume Title

Abstract

Background/Objectives: CT-P13 is a biosimilar version of infliximab, a monoclonal antibody. In individuals with ankylosing spondylitis (AS), CT-P13 has been shown to be effective and to have a well-tolerated safety profile. The aim of this study was to evaluate the long-term drug persistence, safety, and efficacy of infliximab biosimilar CT-P13 in patients with AS undergoing first-line (1st-line) and later (>= 2nd-line) treatment in clinical practice. Methods: We performed an observational cohort study that included AS patients based on the biological drug database in the TURKBIO Registry between 2014 and 2021. The patients were divided into two groups: those receiving CT-P13 as first-line treatment or as a switch (>= 2nd-line) from another TNF inhibitor (TNFi). Standard disease activity metrics were used to assess the effectiveness of CT-P13, and drug retention rates were investigated. Results: There were 179 AS patients using CT-P13 (47.4% male, mean age: 42.9 +/- 11.3 years). Of these patients, 123 (68.7%) were receiving CT-P13 as a first-line treatment. The mean length of treatment was 3.5 years. CT-P13 drug retention rates in the general patient population were 58.6% and 48.2% in the first-line and >= second-line treatment, respectively, after 3 years of follow-up. The most common reason for CT-P13 treatment discontinuation was lack of efficacy. The first-line CT-P13 group had statistically substantially higher ASAS20/40 response rates at three and six months. Nonetheless, both groups' response rates at one year were comparable. Conclusions: In this real-world data analysis, AS patients who were TNFi na & iuml;ve (1st-line) and subsequently treated (>= 2nd-line) with CT-P13 showed encouraging drug retention rates with acceptable long-term effectiveness and safety.

Description

Source:

Keywords:

Keywords

Budget impact analysis, Rheumatoid-arthritis, Biosimilar ct-p13, Double-blind, Innovator infliximab, Parallel-group, Drug survival, Spondyloarthritis, Multicenter, Inhibitors, Ankylosing spondylitis, Biosimilar, Ct-p13, Infliximab, Cohort, Turkbio, Science & technology, Life sciences & biomedicine, Medicine, general & internal, General & internal medicine

Citation

Endorsement

Review

Supplemented By

Referenced By

4

Views

5

Downloads

View PlumX Details